EVIO, Inc. (OTCQB: EVIO) is engaged in quality control testing and consulting company within the legal cannabis industry. Shares of the cannabis testing company are rallying 43.75% through afternoon trading on Wednesday, December 27, 2017. Over the past month, EVIO, Inc. has seen average daily volume of 51,423 shares. However, volume of 364,377 shares or dollar volume of $364,377, has already exchanged hands through afternoon trading today.
Shares of EVIO, Inc. are gaining today after the company announced that its Colorado Licensee, PhytaTech CO, has received the ISO 17025 accreditation, which is the highest quality recognition for testing facilities. PhytaTech now joins EVIO Lab’s in holding the coveted ISO 17025 accreditation. Management says they are continuing to pursue the same accreditation for its labs located in Florida, Massachusetts, and California. Here is the full press release detailing of the accreditation:
EVIO, Inc. Press Release:
BEND, Ore., Dec. 26, 2017 (GLOBE NEWSWIRE) — via NetworkNewsWire — EVIO, Inc. (OTCQB:EVIO), a life sciences company and leading provider of quality control testing and advisory services to the regulated cannabis industry, announced today that its Colorado Licensee, PhytaTech CO, has attained ISO 17025 accreditation. ISO 17025 is the highest recognized quality standard in the world for calibration and testing laboratories. For an organization to be accredited in ISO 17025, its laboratory must be able to consistently produce precise and accurate tests and have implemented a rigorous quality management system.
“As one of only a few Colorado Cannabis Testing labs that have achieved ISO 17025 accreditation, PhytaTech is at the leading edge of testing in the state,” said Stephen Goldman, PhytaTech’s Laboratory Director. “This achievement speaks to our commitment to the highest standards at every step of the testing process.”
“EVIO Labs is proud that PhytaTech is now accredited to the same high-level of standards as our labs in Oregon, which are accredited to the even more highly rigorous ORELAP standard. As we grow, we are committed to ensuring all our labs incorporate the highest quality standards in the industry. We are currently in the process of obtaining ISO 17025 accreditation for our labs in Florida, Massachusetts and California and anticipate full accreditation in the coming months,” commented EVIO CEO William Waldrop.
About PhytaTech CO, LLC.
Located in Denver, CO, PhytaTech has been an industry leader in Colorado as both a licensed medical and retail (adult use) testing provider, servicing licensed cultivators and manufacturers of infused products (“MIPs”) since 2014. In September 2017, PhytaTech CO, LLC entered into a technology license agreement with EVIO Labs Colorado to utilize EVIO Labs’ proprietary testing methods.
About EVIO, Inc.
EVIO, Inc. is a life sciences company focused on analyzing cannabis as a means for improving quality of life. The Company provides analytical testing services, advisory services and performs product research in its accredited laboratory testing facilities. The Company’s EVIO Labs division operating coast-to-coast provides state-mandated ancillary services to ensure the safety and quality of the nation’s cannabis supply.
For more information, visit www.eviolabs.com
Safe Harbor Statement
Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “intends,” “goal,” “objective,” “seek,” “attempt,” or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or www.eviolabs.com
